Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 19, 2018. The document serves as a transaction notification regarding a specific insider transaction rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on a single transaction involving American Depositary Shares (ADSs).
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053
- Transaction Price: $38.0676 per share
- Transaction Volume: 28,572 shares
- Transaction Date: January 18, 2018
- Exchange: New York Stock Exchange (XNYS)
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details an acquisition of ADSs by a Person Discharging Managerial Responsibilities (PDMR) following the re-investment of dividends paid on January 11, 2018, under the Deferred Annual Bonus Plan Post-Tax.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a specific share acquisition event.
Key Facts for Investor Verification
- Verify the identity of the PDMR: Mr. B McNamara, CEO of Consumer Healthcare.
- Confirm the nature of the transaction: Acquisition via dividend re-investment, not an open-market purchase.
- Note the transaction date (January 18, 2018) and price ($38.0676) for comparison against market data on that date.
- Understand that this filing does not reflect the company's overall financial performance for the period.